Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 2,127 Shares

Key Points

• Alpha Tau Medical CFO Raphi Levy sold 2,127 shares on July 1 at an average price of $13.02, bringing in about $27,694 and trimming his ownership by 2.3%. The trade was made under a pre-arranged Rule 10b5-1 plan.
• Levy has also sold shares multiple times in recent weeks, including three larger sales in late June and early June totaling tens of thousands of shares. Those transactions ranged from $9.55 to $12.00 per share.
• DRTS shares rose 1.1% to $12.78, near their 52-week high of $13.06. The company recently reported a quarterly EPS loss that missed expectations, while analysts currently hold a consensus Hold rating with a $12.60 target price.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) CFO Raphi Levy sold 2,127 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $13.02, for a total value of $27,693.54. Following the completion of the transaction, the chief financial officer owned 90,180 shares of the company's stock, valued at $1,174,143.60. This represents a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $11.00, for a total transaction of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total transaction of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Trading Up 1.1%

Shares of Alpha Tau Medical stock traded up $0.14 during trading on Thursday, hitting $12.78. The company's stock had a trading volume of 475,428 shares, compared to its average volume of 577,559. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -19.08 and a beta of 1.16. Alpha Tau Medical Ltd. has a 52 week low of $2.87 and a 52 week high of $13.06. The stock has a 50-day moving average price of $9.64 and a two-hundred day moving average price of $7.79. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Equities research analysts anticipate that Alpha Tau Medical Ltd. will post -0.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Alpha Tau Medical

A number of institutional investors and hedge funds have recently modified their holdings of the business. Mariner LLC grew its position in shares of Alpha Tau Medical by 1.6% during the 4th quarter. Mariner LLC now owns 125,165 shares of the company's stock worth $620,000 after buying an additional 1,915 shares during the period. Trifecta Capital Advisors LLC bought a new position in Alpha Tau Medical during the fourth quarter worth $48,000. Envestnet Asset Management Inc. acquired a new stake in Alpha Tau Medical in the third quarter worth $62,000. Wells Fargo & Company MN increased its stake in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock valued at $116,000 after purchasing an additional 17,500 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new stake in Alpha Tau Medical in the first quarter valued at $132,000. 2.65% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DRTS has been the topic of a number of recent analyst reports. Barclays lifted their price objective on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an "overweight" rating in a research note on Thursday, June 4th. Piper Sandler raised their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a "neutral" rating in a report on Tuesday, May 19th. Citigroup boosted their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, March 11th. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Alpha Tau Medical in a research note on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $12.60.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.